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Abstract
Many antidepressants are cationic amphipaths, which spontaneously accumulate in natural or reconstituted membranes in
the absence of their specific protein targets. However, the clinical relevance of cellular membrane accumulation by
antidepressants in the human brain is unknown and hotly debated. Here we take a novel, evolutionarily informed approach
to studying the effects of the selective-serotonin reuptake inhibitor sertraline/ZoloftH on cell physiology in the model
eukaryote Saccharomyces cerevisiae (budding yeast), which lacks a serotonin transporter entirely. We biochemically and
pharmacologically characterized cellular uptake and subcellular distribution of radiolabeled sertraline, and in parallel
performed a quantitative ultrastructural analysis of organellar membrane homeostasis in untreated vs. sertraline-treated
cells. These experiments have revealed that sertraline enters yeast cells and then reshapes vesiculogenic membranes by a
complex process. Internalization of the neutral species proceeds by simple diffusion, is accelerated by proton motive forces
generated by the vacuolar H
+-ATPase, but is counteracted by energy-dependent xenobiotic efflux pumps. At equilibrium, a
small fraction (10–15%) of reprotonated sertraline is soluble while the bulk (90–85%) partitions into organellar membranes
by adsorption to interfacial anionic sites or by intercalation into the hydrophobic phase of the bilayer. Asymmetric
accumulation of sertraline in vesiculogenic membranes leads to local membrane curvature stresses that trigger an adaptive
autophagic response. In mutants with altered clathrin function, this adaptive response is associated with increased lipid
droplet formation. Our data not only support the notion of a serotonin transporter-independent component of
antidepressant function, but also enable a conceptual framework for characterizing the physiological states associated with
chronic but not acute antidepressant administration in a model eukaryote.
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Introduction
Cationic amphiphilic/amphipathic drugs (CAD) represent a
subset of Food and Drug Administration (FDA) approved
compounds that promiscuously interact with both proteinaceous
and non-proteinaceous targets, the latter being cellular mem-
branes [1,2]. CAD association with cellular membranes depends
on an ionizable amine that is positively charged at physiological
pH and a lipophilic polycyclic scaffold, but does not depend on
stereochemistry, as in the peculiar case of the antidepressant
sertraline/ZoloftH moonlighting as a fungicide [3]. The primary
protein target of sertraline is thought to be the human serotonin
transporter (hSERT), which localizes to synaptic clefts and recycles
the monoamine neurotransmitter serotonin after each burst of
neurotransmission. According to the monoamine hypothesis of
depression, antidepressants like sertraline bind hSERT and acutely
block reuptake of serotonin in the brain [4]. However, a latency
period whose molecular basis is unknown precedes the emergence
of the actual antidepressant effect in humans, and in rodent
behavorial models of depression, suggesting that antidepressants
exert additional effects at targets besides hSERT. Given the well
known and wide-ranging effects of CAD on cellular membrane
homeostasis in the absence of specific proteins targets [5,6], the
clinical relevance of antidepressant accumulation in neuronal cell
membranes has been vigorously debated. For example, there is
evidence that supports the existence of serotonin transporter-
independent components of antidepressant function in vertebrate
cellular models [7], some of which appears to involve membrane
accumulation by antidepressants [8,9]. Yet a comprehensive
model of antidepressant function that accounts for all drug-target
interactions in the human brain has so far been elusive.
The goal of the present study is to begin developing and
validating a comprehensive model of complex antidepressant
function in humans. The first step in this arduous process is to
reconcile two pharmacological perspectives that have historically
dominated conventional thinking about CAD activity in cells
lacking specific integral membrane protein targets. On the one
hand, a molecular view of drug-membrane interactions derives
from the seminal work of Singer and Sheetz on amphipath-
induced morphological transformations of freshly isolated human
erythrocytes, a cell-based model system superior to reconstituted
liposomes but still lacking endomembranes. Singer and Sheetz
proposed the bilayer couple/balance model, which states that a
charged amphipath preferentially accumulates at equilibrium in
the leaflet (monolayer) exhibiting the opposite net charge [10]. A
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34024disparity in inter-leaflet surface area of less than 1% resulting from
asymmetric partitioning by charged amphipaths can be readily
observed as dramatic macroscopic changes in the topology of the
erythrocyte plasma membrane. On the other hand, a physiological
view was developed around the same time by Christian de Duve
and colleagues, and is called lysosomotropism, or ‘‘ion trapping.’’
Lysosomotropism is defined as the concentrative capacity of acidic
organelles to trap protonated weak bases within, and cannot be
modeled by red blood cells [11]. Lysosomotropism has been
documented in various mammalian cell lines and in whole
organisms treated with CAD.
Here we build on an effort begun in our previous study of
sertraline-induced ‘‘overdose’’ [12], in which we demonstrated
that the model eukaryote Saccharomyces cerevisiae (budding yeast) is
an ideal experimental system in which to combine the biophysical
insights of the bilayer couple model with the physiological insights
of lysosomotropism. In that study, we reported the isolation and
genetic characterization of sertraline overdose-resistant mutants
(sert
R) with altered clathrin function or reduced vacuolar H+-
ATPase complex activity. Others have also shown that yeast is
amenable to studying cellular membrane accumulation by CAD
[13–15]. However, a caveat of our previous study is that selection
for (sert
R) mutants required supra-therapeutic (,10
25 M) drug
concentrations. Here we applied techniques of classical pharma-
cology to yeast, which enabled us to measure membrane
accumulation by radiolabeled sertraline – hereafter [
3H]sertraline
– at clinically relevant (,10
29 M) concentrations. We conclude
the present study by proposing an evolutionarily informed model
of antidepressant function that may provide a molecular basis for
neurotrophism induced by chronic treatment with antidepressants
in rodent models of human depression, and by extension the
therapeutic lag observed in patients taking antidepressants.
Results
Two thermodynamic drivers of sertraline entry into yeast
cells
We treated wildtype BY4716 cells (hereafter ‘‘wildtype) with
[
3H]sertraline, which we obtained by custom synthesis (see
Materials and Methods). We report a total [
3H]sertraline cellular
accumulation (Bmax) equal to 0.019 picomoles (pmol) per 10
7 cells
(+/20.0014 SEM), and a half-maximal [
3H]sertraline cellular
uptake rate equal to 3.1 minutes (+/20.97 SEM) (Fig. 1A). These
data are consistent with the lysosomotropic mechanism originally
described de Duve and colleagues [11]. Briefly, as the pH of the
extracellular medium increases, the deprotonation of sertraline is
favored; the ratio of neutral to cationic species reaches unity at the
pKa of sertraline. Neutral sertraline is membrane-permeable while
charged sertraline is not. Therefore, more [
3H]sertraline is
internalized by cells growing in alkaline media compared to acidic
media. Several classical studies showed that cellular uptake and
accumulation of radiolabeled tricyclic antidepressants by primary
neurons and fibroblast cell lines is lysosomotropic and Na
+-
independent [16,17].
However, [
3H]sertraline cellular uptake is only partially
dependent on proton motive forces generated by vacuolar H
+-
ATPase complexes (V-ATPases) [18], which can be specifically
inhibited by the macrolide antibiotic bafilomycin A (BAF). Pre-
treatment of wildtype cells with BAF for 30 minutes resulted in a
65% reduction in [
3H]sertraline cellular accumulation compared
to the control condition, while treatment of wildtype cells with
BAF 30 minutes after exposure to [
3H]sertraline resulted in
reduced [
3H]sertraline cellular accumulation that was 57% of
the control amount (Fig. 1B). We performed four controls in
order to demonstrate the specificity of V-ATPase-dependent
proton motive forces. First, a dnf1,2,3D triple mutant, which
exhibits constitutive vacuolar hyper-acidification [19], significantly
hyper-accumulates [
3H]sertraline while the vma9 mutant, which
exhibits constitutive vacuolar alkalinization, hypo-accumulates
[
3H]sertraline (Fig. 1C). Second, the effects of BAF on
[
3H]sertraline accumulation are completely abolished in a vma9
(YCL005W-A) mutant, which normally encodes subunit e of the V0
subunit of the V-ATPase complex (Fig. 1B). Third, before and
after treatments of wildtype cells with oligomycin, a specific
chemical inhibitor of the F1-F0 mitochondrial ATPase, actually
resulted in slightly increased [
3H]sertraline accumulation
(Fig. 1B). Fourth, FCCP, a non-specific proton ionophore,
phenocopies the effects BAF but co-administration of these two
agents does not exhibit additivity (Fig. 1B). Interestingly, single
cells overdose in the presence of sertraline in a stochastic manner
(Fig. 1D). Thus, at the population level and at the level of single
cells, the cellular uptake of [
3H]sertraline appears to be non-
uniform; a fraction of internalized sertraline is ‘‘ion trapped,’’
while the remainder is associated with cellular membrane sites.
Next we measured [
3H]sertraline cellular uptake and accumu-
lation in response to several environmental perturbations that
affect cellular membrane function globally. First, we examined the
effect of low temperature, as low temperature promotes the liquid
crystalline-gel transition of membranes, i.e., decreases membrane
fluidity. Membrane fluidity has been shown to be a determinant of
local anesthetic partitioning into reconstituted liposomes [20]. The
initial rate of [
3H]sertraline cellular uptake by wildtype cells is four
times slower at 0uC versus 25uC; after 60 minutes, cells incubated
at 0uC accumulate 45% of the total [
3H]sertraline taken up by
isogenic cells incubated at 25uC( Fig. 2A). To rule out that low
temperature mediates this dampening effect through cessation of
vesicle-mediated transport, we also measured [
3H]sertraline
cellular accumulation by a sec18
ts mutant, which is conditionally
unable to perform membrane-membrane fusion reactions after
temperature up-shift [21]. We observed no significant differences
between sec18
ts and its wildtype reference after a short (25 minute)
or long (60 minute) incubation at the non-permissive temperature
(Fig. 2B). Next, we tested whether [
3H]sertraline cellular uptake
and accumulation depends on energy. We pretreated wildtype
cells with a cellular ATP depleting cocktail containing 10 mM
sodium azide and 10 mM 2-deoxy-D-glucose. Total [
3H]sertraline
cellular accumulation was increased 3.4-fold in the presence of
energy poisons (Fig. 2C). We interpret this result to mean that
energy-dependent xenobiotic efflux pumps constitutively extrude
[
3H]sertraline from the cell. Thus, the association of [
3H]sertraline
with cellular membranes appears to depend on bulk physical
properties of the bilayer.
Sertraline permeates vesiculogenic membranes
We characterized the subcellular distribution of [
3H]sertraline
in wildtype cells by biochemical fractionation experiments. As
shown in Figure 3A, over 80% of intracellular [
3H]sertraline
sediments in the P10,000 fraction following osmotic lysis; that
percentage climbs to 90% after mechanical lysis (Fig. 3B). After
accounting for the trace amount of [
3H]sertraline present in the
P100,000 microsomal fraction, only 10–15% of intracellular
[
3H]sertraline appears to be truly soluble, demonstrating that at
equilibrium the vast majority of [
3H]sertraline stably partitions
into cellular membranes, presumably as a neutral species. To
verify that [
3H]sertraline partitioned into cellular membranes we
performed the same experiment but in the presence of the
nonionic detergent Triton X-100. Triton X-100 completely
solubilizes P10,000-associated [
3H]sertraline (P,0.0001, ANOVA;
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sites may not be chemically uniform. We reasoned that we could
distinguish between at least two types of membrane association –
adsorption (topical) versus intercalation (deep) – on the basis of
chemical extractability of [
3H]sertraline from the P10,000 fraction.
The results of this analysis are presented in Figure 3B. Chemical
agents that disrupt electrostatic interactions (e.g., 0.5 M Tris)
either have no or little solubilizing effect on membrane-associated
[
3H]sertraline, while chemical agents that disrupt hydrophobic
interactions, including the mild detergent digitonin, solubilize
membrane-associated [
3H]sertraline to varying degrees. Proteo-
lytic digestion of surface-exposed membrane proteins has a modest
solubilizing effect, ruling out membrane proteins as essential for
amphipath-membrane association. Interestingly, excess (100 mM)
‘‘cold’’ sertraline only has a modest solubilizing effect, which is
consistent with the notion that sertraline is buried in the
hydrophobic phase of the bilayer at equilibrium.
AP 10,000 fraction is thought to be enriched in large organelles
like vacuoles and mitochondria at the expense of small organelles
like Golgi and ER. As an initial attempt to biochemically purify
sertraline-associated cellular membranes, we performed analytical
density-gradient centrifugation on a P100,000 fraction after a single-
step centrifugation of lysates from wildtype cells. A single peak
spanning two fractions of intermediate density (refractive index in
the range 1.37–1.38) contains on average ,70% of membrane-
associated [
3H]sertraline, with ,60% concentrated in a single
fraction (fraction 6) (Fig. 3C). We screened these gradient
fractions against a panel of antibodies specific for markers residing
in different subcellular compartments, and densitometry plots are
shown for each marker in Figure 3D. Although our gradient had
limited resolving power at fractions 6–7, we observed the strongest
co-localization of markers specific for ER and vacuolar membrane
markers, as well as the vacuolar resident enzyme carboxypepti-
dase, with the [
3H]sertraline peak in fraction 6, but we did not
observe co-localization with a plasma membrane marker (data not
shown). We observed less albeit still significant co-localization of
Golgi and endosomal membrane markers with [
3H]sertraline,
though these markers themselves peak in the slightly denser
fraction 7. Although the mitochondrial marker porin is also
present in fractions 6–7, we showed above that disrupting proton
motive forces with oligomycin actually increased [
3H]sertraline
accumulation (Fig. 1B), so while association with mitochondrial
cannot be ruled out it appears coincidental.
Figure 1. [
3H]sertraline cellular uptake and accumulation is rapid, partially lysosomotropic and varies from cell to cell. (A) Wildtype
BY4716 cells accumulate [
3H]sertraline (picomoles of radioligand/10
7cells) in a time-dependent manner as a function of ambient pH: pH 6.0
(diamonds); pH 6.5 (triangles); pH 7.0 (squares). Notice the break in the x-axis between 10 and 20. (B) Bar graph showing fraction of [
3H]sertraline
accumulated with a 30-minute 2 mM bafilomycin A pre-treatment (‘‘before’’) compared to no bafilomycin A pre-treatment; and fraction of
[
3H]sertraline accumulated with a 30-minute 2 mM bafilomycin A-post-treatment (‘‘after’’) compared to no bafilomycin A post-treatment. Wildtype
BY4716 (black, unfilled) is contrasted with a vma9 mutant (black, filled). Before and after treatments of wildtype BY4716 treated with 1 mM FCCP (blue,
unfilled), 1 mM FCCP+2 mM bafilomycin A (blue, filled), or 10 mg/mL oligomycin (red, unfilled) are also shown. Statistical significance determined by
two-tailed t-test. *** P=0.0004; * P=0.0118. (C)[
3H]sertraline uptake and accumulation time course with wildtype BY4742 cells (black circles, filled) a
dnf1D dnf2D dnf3D triple mutant cells (red circles, filled), and a vma9 mutant (red circles, unfilled). Notice the break in the y-axis between 0.02 and
0.05. (D) Single-cell dose response of sertraline-induced cytotoxicity (‘‘overdose’’) for wildtype BY4716 (black), vma9 (red), and cup5 (cyan) cells. Error
bars indicate SEM. Means were generated from three independent biological replicates.
doi:10.1371/journal.pone.0034024.g001
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sertraline sensitivity
We reasoned that comparison of measurements of [
3H]sertra-
line cellular uptake and accumulation in a panel of mutant strains
with altered sertraline cellular response would allow us to develop
a cell biological model of cellular membrane accumulation by
sertraline. The wildtype strain serves as a reference for three
previously described de novo sert
R mutants: vma9 (described above),
swa2 (YDR320C) and chc1 (YGL206C) [12]. ACY769 is a wildtype
prototrophic strain derived from S288c (hereafter ‘‘prototroph’’),
which serves as a reference for four sertraline-hypersensitive
(sert
HS) homozygous gene deletion mutants involved in clathrin
coat formation: arf1D, cdc50D, drs2D and sac1D. ARF1 (YDL192W)
encodes a small GTPase that is thought to be a master regulator of
vesiculogenesis at internal membranes. DRS2 (YAL026C) encodes
an aminophospholipid flippase that localizes to Golgi and
endosomal membranes, and CDC50 (YCR094W) encodes its
regulatory subunit. SAC1 (YKL212W) encodes a lipid phosphatase
with specific activity against phosphatidylinositol 4-phosphate
(PIP), and localizes to the endoplasmic reticulum (ER) and Golgi.
Together these sert
R and sert
HS mutants comprise a ‘‘vesiculogen-
esis’’ module centered around ARF1 and PIP, as deletion of ARF1
is synthetically lethal with loss of SWA2, DRS2 or CDC50 [22,23].
Total [
3H]sertraline cellular accumulations (Bmax) for each of the
mutants appear in Table 1.
Unlike the vma9 mutant or BAF-treated wildtype cells, the chc1
mutant and to a lesser extent the swa2 mutant, unexpectedly
hyper-accumulate [
3H]sertraline. Therefore it may be more
appropriate to classify chc1 and swa2 mutants as ‘‘sertraline-
tolerant.’’ This hyper-accumulation is distinct from that exhibited
by dnf1,2,3D, as both chc1 and swa2 have a constitutive vacuolar
acidification defect that phenocopies V-ATPase deficiency [12].
Controlling for cell number and cell size, we observed that two
other mutants hyper-accumulate [
3H]sertraline: sac1D and arf1D.
drs2D and cdc50D mutants are indistinguishable from the control
condition. These results indicate that there are at least two
qualitatively distinct phases of the cellular response to sertraline:
the first phase affects acute sertraline uptake, while the second
phase, which is typified by drs2D, has no effect on acute sertraline
uptake, and so instead must be involved in the adaptation to
chronic sertraline exposure.
To explore this phenomenon more rigorously, we measured the
kinetics of [
3H]sertraline cellular uptake as a function of substrate
concentration. Kinetic experiments with both wildtype references
and mutants with altered sertraline cellular response indicate a
single non-saturable component of [
3H]sertraline cellular uptake,
i.e., internalization by simple diffusion (Fig. 4A–B). We estimate
Vmax to be 0.62 pmol [
3H]sertraline/10
7 cells/min, which
translates to ,1000 sertraline molecules per cell per minute
subject, of course, to individual differences between clones. We
estimate the Km of sertraline to be 71.5 nM, which represents
high-affinity binding but less than the affinity exhibited by it for
the human serotonin transporter [24]. The panel of mutants
exhibited a range of acute [
3H]sertraline cellular uptake rates.
Neither vma9 nor drs2D mutants show a measurable difference in
the rate of [
3H]sertraline cellular uptake compared to wildtype.
However, as expected chc1, swa2, arf1D and sac1D take up more
[
3H]sertraline per unit time, in the order sac1D.ch-
c1=arf1D.swa2. Acute sertraline hyper-accumulation appears to
have two different molecular bases, as indicated by the results of
screening the mutants on a secondary phenotype of BAF-induced
release of internalized [
3H]sertraline (Fig. 4C–D).
Among the sert
R mutants, swa2 is more resistant to the effects of
BAF than wildtype, while chc1 is unchanged compared to wildtype,
Figure 2. Solubility properties of cellular membranes affect the
rate and extent of [
3H]sertraline accumulation. (A) One-hour time
course of [
3H]sertraline accumulation in BY4716 cells incubated at 25uC
(black circles, filled), wildtype incubated at 0uC (black circles, unfilled).
Low temperature values were normalized by room temperatures values
for ease of comparison. (B)[
3H]sertraline accumulation was measured in
wildtype BY4742 cells (unfilled) and sec18
ts mutant cells (hatches).
Times indicate duration of radioligand exposure at 37uC. (C) Total
[
3H]sertraline accumulation in the presence and absence of energy
poisons. Statistical significance determined by two-tailed t-test. *
P=0.0113. Error bars indicate SEM. Means were generated from three
independent biological replicates (except for (B), which was generated
from two independent biological replicates).
doi:10.1371/journal.pone.0034024.g002
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association may be complexly regulated by the rate of clathrin
assembly and disassembly. The sac1D mutant appears to
accumulate sertraline by a completely distinct mechanism. sac1D
cells exhibit a near 20% reduction in the fraction of [
3H]sertraline
retained after inhibition of V-ATPase complexes compared to
wildtype (Fig. 4D). This result suggests that another component of
sertraline’s cellular membrane association may be regulated by the
levels of the phosphoinositide PIP. Phosphoinositides have been
shown to constitute anionic binding sites for CAD at the interfacial
region of the bilayer in addition to the phosphate groups forming
the backbone of glycerophospholipids [25]. We also observed that
cell growth rate in the presence of overdose concentrations of
sertraline is not correlated with the rate of nanomolar [
3H]sertra-
line cellular uptake, as clearly demonstrated by a comparison
between the sert
HS mutants sac1D and drs2D (Fig. 4E–F). This
result demonstrates that phospholipid asymmetry, as opposed to
membrane anionicity per se, is a key component of the adaptive
physiological response to chronic cellular membrane accumulation
by sertraline, as was originally proposed by Huestis and colleagues
in experiments on erythrocytes [26].
Ultrastructural analysis of autophagy induction and
membrane quality control
The pharmacological and biochemical experiments described
above localize sertraline to vesiculogenic membranes. We
therefore performed an ultrastructural examination of organellar
membrane homeostasis on yeast cells exposed to 60 mM sertraline
for 45 minutes, which constitutes a sub-lethal chronic treatment
(Fig. S1). If the bilayer couple model holds, then exogenous
cationic amphipaths will favor the more negatively charged leaflet
of organellar membranes. In the specific case of sertraline, we
expected to find examples of damaging local curvature stress in
membranes comprising the vesicular transport pathway. Initial
support for this hypothesis was found in the observation that
micromolar sertraline treatment has three noteworthy effects on
vacuole homeostasis, which serves as a quantitative cell biological
read out. First, we observed a decrease in the number vacuoles per
cell in wildtype cells treated with 60 mM sertraline (Fig. 5A). The
percentage of vacuole-less cells increases (36% vs. 12%) as does the
percentage of cells containing one large consolidated vacuole (49%
vs. 29%). In fact, loss of vacuoles was observed in all strains treated
with 60 mM sertraline (Fig. 5B–H). Second, the steady-state
distributions of vacuoles per cell are increased relative to wildtype
Figure 3. Subcellular fractionation demonstrates [
3H]sertraline accumulation in vesiculogenic membranes. (A) The percent
[
3H]sertraline detected in soluble (‘‘S’’) versus pellet (‘‘P’’) fractions following sequential centrifugations (10,0006g and 100,0006g) in the absence
(white columns) or presence of 0.5% Triton X-100 detergent (hatches). (B) The ratio of soluble (yellow) to P10,000-associated (blue) [
3H]sertraline
following extraction with a diverse panel of chemical agents. * P,0.05, ANOVA; ** P,0.0001, ANOVA. (C) Distribution of [
3H]sertraline across ten
equal volume fractions following Optiprep gradient separation of total organellar membranes (P100,000) from wildtype BY4716 cells treated with
[
3H]sertraline for one hour at 25uC. The refractive index is plotted (blue slashed line) on the left y-axis. (D) Densitometry plots of six organellar markers
distributed across the ten gradient fractions. Error bars indicate SEM. Means were generated from three independent biological replicates.
doi:10.1371/journal.pone.0034024.g003
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of the sert
HS mutant arf1D exhibits polygonal and tubulated
morphologies (Fig. 5H), while the vacuoles of the sert
R mutants
chc1 and swa2 by and large exhibit wildtype vacuolar morphology.
However, the vacuoles of chc1 and swa2 cells are more likely to
have regions of thickened bilayer (Fig. 5D, inset). The seminal
study by Lieber et al documented membrane thickening in
erythrocytes bathed in the phenothiazine chlorpromazine [27].
Third, we observed a sharp increase in the percentage of electron-
lucent wildtype vacuoles (24% vs 97%) (Fig. 5A, inset), and
comparable increases were observed across all the strains (Fig. 5,
red insets).
We reasoned that the distribution of vacuoles per cell would
allow us to test the hypothesis that sertraline hyper-accumulation is
caused by an increase in the surface-area-to-volume ratio of
vacuoles or other V-ATPase-acidified organelles of the vesicular
transport pathway. The steady-state number of vacuoles per cell
separates the four sertraline hyper-accumulating mutants into two
unequal groups. Group One is arf1D, chc1, and swa2, three genes
that interact physically and genetically [22]. Group Two is sac1D;
sac1D cells accumulate the phosphoinositide PIP, which recruits
and activates ARF1 and presumably stimulates vesiculogenesis.
Changes in the number or surface-area-to-volume ratio of
organelles may explain the hyper-accumulation phenotype of
Group One mutants, but does not appear to explain the hyper-
accumulation phenotype of sac1D cells, which have fewer vacuoles
per cell at steady state. Also, the vacuolar membranes of sac1D cells
appear to have an aberrant crenated morphology (Fig. 5F, inset).
The spike in electron lucency combined with a reduction in the
total number of vacuoles per cell is accompanied by the
appearance of double membrane-bound autophagosomes, a tell-
tale sign of autophagy. A typical sertraline-treated wildtype cell
after five minutes of exposure to 60 mM sertraline is illustrative
(Fig. 6A). Changes in gross vacuolar morphology, electron
lucency, and fine vacuolar membrane structure are typical of
sertraline-treated cells at all time points, and a magnified view of a
representative vacuole highlights the salient changes (Fig. 6B).
The aberrant multilamellar membranous structure marked by an
asterisk in Figure 6A is clearly encased in an autophagosome
(Fig. 6C). Quantification of autophagosomes like those appearing
in Figure 6C–D in wide-field images corroborates the single-cell
snapshots: untreated wildtype cells contain on average 0.11
Table 1. Total [
3H]sertraline cellular accumulation (Bmax) as a function of pH. Bmax is defined as pmol/10
7 cells/hour.
Bmax Bmax 95% CI r
2
BY4716 0.00558 (+/20.000532) 0.00448 to 0.00669 0.593
chc1 0.0199 (+/20.00288)** 0.0139 to 0.0259 0.403
swa2 0.0118 (+/20.00127)** 0.00919 to 0.0144 0.457
vma9 -- -
pH 6.0 ACY769 0.0109 (+/20.000767) 0.00933 to 0.0124 0.522
drs2D 0.0166 (+/20.000805)
ns 0.0149 to 0.0183 0.881
cdc50D 0.0183 (+/20.00114)
ns 0.0159 to 0.0206 0.844
arf1D 0.0168 (+/20.00223)
ns 0.0122 to 0.0215 0.462
sac1D 0.0399 (+/20.00250)** 0.0343 to 0.0447 0.826
Bmax Bmax 95% CI r
2
BY4716 0.0189 (+/20.00140) 0.0161 to 0.0217 0.575
chc1 0.0363 (+/20.00591)* 0.0240 to 0.0486 0.333
swa2 0.0196 (+/20.00245)
ns 0.0145 to 0.0247 0.499
vma9 0.0142 (+/20.00111) 0.0119 to 0.0165 0.750
pH 6.5 ACY769 0.0326 (+/20.00136) 0.0299 to 0.0353 0.864
drs2D 0.0401 (+/20.00224)
ns 0.0355 to 0.0447 0.873
cdc50D 0.0410 (+/20.00295)
ns 0.0348 to 0.0471 0.835
arf1D 0.0747 (+/20.00688)* 0.0605 to 0.0890 0.750
sac1D 0.0896 (+/20.00857)** 0.0718 to 0.107 0.685
Bmax Bmax 95% CI r
2
BY4716 0.0292 (+/20.00217) 0.0248 to 0.0337 0.826
chc1 0.0750 (+/20.00633)** 0.0619 to 0.0882 0.682
swa2 0.0797 (+/20.00533)** 0.0686 to 0.0907 0.847
vma9 -- -
pH 7.0 ACY769 0.0639 (+/20.00203) 0.0599 to 0.0680 0.925
drs2D 0.0724 (+/20.00460)
ns 0.0628 to 0.0819 0.900
cdc50D 0.0717 (+/20.00516)
ns 0.0610 to 0.0824 0.860
arf1D 0.128 (+/20.0159)
ns 0.0946 to 0.161 0.715
sac1D 0.246 (+/20.0148)** 0.215 to 0.277 0.877
doi:10.1371/journal.pone.0034024.t001
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increase of 4.2-fold. Multilamellar structures encapsulated by
autophagosomes were observed in wildtype cells at all time points.
Interestingly, similar membranous structures have been observed
in brain tissues of rodents treated with the illicit psychoactive CAD
3,4-Methylenedioxymethamphetamine (MDMA) [28]. Two par-
Figure 4. Altered kinetics of [
3H]sertraline cellular uptake in sertraline-resistant (sert
R) and sertraline-hypersensitive (sert
HS)
mutants. (A) Kinetic analysis of [
3H]sertraline cellular uptake after two minutes for sert
R mutants (chc1, swa2 and vma9). (B) Kinetic analysis of
[
3H]sertraline cellular uptake after two minutes for sert
HS mutants (arf1D, drs2D and sac1D). The concentrations of [
3H]sertraline tested were
0.3125 nM, 0.625 nM, 1.563 nM, 3.125 nM, 6.25 nM, 12.5 nM, and 25 nM. Wildtype reference strains are plotted as black unfilled circles. Strains are
identified by a fixed color scheme. Before and after treatments with bafilomycin A are shown for sert
R (C) and sert
HS (D) strains. Multi-hour growth
curve for wildtype and thre sertraline-hypersensitive mutants. Growth in the absence (E) and in 20 mM sertraline (F) are shown. Statistical significance
determined by two-tailed t-test: * P,0.05; ** P,0.01. Fits were generated by nonlinear regression. Error bars indicate SEM. Means were generated
from three independent biological replicates.
doi:10.1371/journal.pone.0034024.g004
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e34024Figure 5. Vacuolar number, morphology and contents assessed from transmission electron micrographs of untreated and
sertraline-treated cells. (A) BY4716; (B) vma9;( C) swa2;( D) chc1;( E) prototroph; (F) sac1D;( G) drs2D;( H) arf1D. For each strain, the distribution of
vacuoles per cell is shown for a population of untreated cells (black columns) and 60 mM sertraline-treated cells (red columns). Insets contain a
representative vacuole from the untreated (black outline) and 60 mM sertraline-treated (red outline) populations.
doi:10.1371/journal.pone.0034024.g005
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arrows mark the sites where two unilamellar vesicles, one of which
contains a densely packed membranous whorl, are clearly
discerned from the outer membrane of the autophagosome. And
in Figure 6E, lamellar plumes of membrane form a Medusa-like
structure trapped inside a large electron-lucent vacuole.
If autophagy is triggered by sertraline accumulating in
organellar membranes, one would expect to observe ultrastruc-
tural evidence of membrane curvature stress throughout the
vesicular transport pathway, not just in vacuolar membranes. In
this instance, a representative wildtype cell treated with 60 mM
sertraline for 45 minutes is illustrative (Fig. 7A). The structure
marked by an asterisk is a shown at higher magnification to be a
dilated cisterna, possibly a Golgi stack or an autophagosomal
precursor, with circular or crescent morphology (Fig. 7B). Similar
structures were observed in other sertraline-treated cells at this
time point, including an example of a dilated cisterna with clearly
thickened membranes on the convex surface. (Fig. 7C). Compar-
ison of an untreated arf1D cell to a sertraline-treated arf1D cell
reveals several localized exaggerated regions of membrane
expansion in comparable organellar structures (Fig. 7D–E).
Finally, two mutants, chc1 and swa2, exhibited a unique
ultrastructural phenotype that may be involved in adaptive
cellular pathways that degrade and regenerate cellular membranes
infiltrated by exogenous cationic amphipaths. At steady state, chc1
and swa2 mutants exhibit a vacuolar expansion/fragmentation
phenotype that is ‘‘normalized’’ after 60 mM sertraline treatment
for 45 minutes insofar as the number of vacuoles per cell decreases
(Fig. 5C–D). However, these vacuoles exhibit a non-random
distribution of osmiophilic lumenal contents and appear to contain
undigested vesicular compartments (Fig. 8B). Interesting, the
number of lipid droplets, which are storage depots for neutral
lipids (e.g., triglycerides) and marked by red asterisks (Fig. 8B),
increased after sertraline treatment in wildtype and sert
R and
sert
HS mutant strains by an unknown mechanism (Fig. 8C). This
increase is most pronounced in sertraline-treated chc1 and swa2
cells; untreated chc1 cells have a mean lipid droplet count equal to
0.32, while sertraline-treated chc1 cells have a mean lipid droplet
count equal to 2.2. By contrast, untreated wildtype cells have a
mean lipid droplet count equal to 0.31, while sertraline-treated
wildtype cells have a lipid droplet count equal to 0.55. One
explanation for this result is that lipid droplets form during
adaptation of yeast cells to secretory pathway stress, as has been
suggested by others [29].
Discussion
We presented evidence that supports an evolutionarily
informed, cell biological explanatory model of cellular membrane
accumulation by sertraline in a simple eukaryote with an intact
secretory pathway. Explication of our model begins with the
passive internalization of neutral sertraline molecules at the plasma
membrane. Lysosomotropism acts as an amplifier of simple
diffusion, and suggests a mechanism whereby sertraline may
distribute non-uniformly throughout vertebrate tissues as a result
of tissue-specific activity or regulation of V-ATPase-dependent
acidification [30]. The internalization of sertraline appears to
follow an entry route that is orthogonal to ATP-dependent, SEC
gene-requiring internalization of larger aryl cationic amphipaths
(e.g., lysophospholipids), i.e., does not depend on the endocytic
pathway [31]. However, passively internalized sertraline appears
to be a potent substrate for ATP-dependent efflux pumps. In fact,
efflux may explain the paradoxical observation that at physiolog-
ical pH, sertraline is predicted to be over 99% ionized yet only a
minority fraction (10–15%) is observed to be soluble at
equilibrium. Our interpretation is that the ionized pool of
Figure 6. A time course of sertraline treatment reveals early and persistent induction of autophagy and the appearance of aberrant
multilamellar structures. (A) Representative 60 mM sertraline-treated wildtype BY4716 cell after 5 minutes of sertraline treatment. Magnification is
6,3006(scale bar=0.5 micron). The lone vacuole of the cell in (A) is shown at higher magnification (16,0006; scale bar=0.1 micron) in panel (B). The
black asterisk denotes an autophagosome that has encapsulated a membranous whorl, which is shown at higher magnification (25,0006; scale
bar=0.1 micron) in (C). The black arrows in (D) mark the telltale double membrane of an autophagosome at higher magnification (25,0006; scale
bar=0.1 micron). An elaborated multilamellar structure from a BY4716 cell treated with 60 mM sertraline for 20 minutes is shown at higher
magnification (16,0006; scale bar=0.1 micron) in (E).
doi:10.1371/journal.pone.0034024.g006
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sequestration in cellular membranes as a neutral species.
Despite our best efforts to separate vesiculogenic membranes
into discrete organelles by density-gradient centrifugation, parsi-
mony dictates that sertraline asymmetrically accumulates in the
membranes of all V-ATPase-acidified organelles, presumably in
proportion to local lysosomotropic driving forces. Specifically,
sertraline associates with organellar membranes by two mecha-
nisms: adsorption to solvent-exposed anionic sites, and intercala-
tion into the bulk hydrophobic phase of the bilayer. A two-state,
weakly binding and strongly binding model has been proposed for
local anesthetic association with reconstituted liposomes [32], and
we argue that adsorptive binding by sertraline in yeast cells may be
mediated by electrostatic interactions, while intercalative binding
by sertraline in yeast cells may be mediated by lipophilic
interactions. However, several uncertainties remain in part
because in vivo experiments on CAD in living cells are unlike
experiments on CAD in reconstituted liposomes, in which the
ionization state of CAD can be experimentally manipulated.
Therefore, we conclude that sertraline-membrane association is a
composite of more than one binding interaction, a conclusion
supported by molecular dynamic simulations [33,34].
The central finding of our study is that at micromolar doses,
cellular membrane accumulation by sertraline induced curvature
stresses throughout the organelles of the vesicular transport
pathway. This membrane curvature stress triggers an autophagy-
dependent membrane quality control response that appears to be
enhanced in mutants with altered clathrin function. Although we
have not provided biochemical evidence of autophagy induction,
our ultrastructural approach revealed unambiguous induction of
autophagy. We argue that autophagy mitigates cationic amphi-
path accumulation in cellular membranes. This interpretation is
supported by a recent study that documented induction of
autophagy by antidepressants in mammalian neuronal cell lines
[35]. Autophagy may be one of several buffering systems that
evolved to preserve cellular membrane homeostasis in the face of
endogenous (or exogenous) charged amphipath accumulation, but
when sertraline-induced membrane curvature stresses become too
punishing at high or sustained doses, cytotoxicity ensues [36].
However, the cell-physiological effects of sub-lethal doses of
sertraline may not be deleterious. We previously showed that low
micromolar sertraline partially rescues the constitutive growth
defect of yeast mutants with altered clathrin function [12]. If these
buffering systems are defective due to genetic (e.g., clathrin
dysregulation) and/or environmental stressors – resulting in a
maladaptive homeostatic set point – sub-lethal accumulation of
amphipath may normalize this set point. A ‘‘trophic’’ or
cytoprotective effect might ensue given the ancient coupling
between membrane transport and cell growth [37]. A similar
argument was proffered by researchers explaining the cytotoxic
effects of the phenothiazine antipsychotic drug chlorpromazine in
yeast cells [13]. In conclusion, our model supports the notion of a
serotonin transporter-independent component of antidepressant
pharmacology in humans, and appears to buttress the neuro-
trophic hypothesis of depression [38]. It is tempting to speculate
that amphipath accumulation may, in specific contexts, provide a
trophic signal through direct modulation of the physical properties
of cellular membranes, perhaps resulting in vesicle formation,
thereby exploiting (or ‘‘short-circuiting’’) the aforementioned
coupling between membrane transport and cell growth. Such a
Figure 7. Ultrastructural evidence of local membrane curvature stress in sertraline-treated cells. (A) Representative 60 mM sertraline-
treated wildtype BY4716 cell at 8,0006 (scale bar=0.5 micron). Asterisk denotes circularized Golgi-like structure, which is shown at higher
magnification (31,5006; scale bar=0.1 micron) in (B). An enlarged Golgi-like cisterna with visible expansion of the convex membrane from a 60 mM
sertraline-treated wildtype prototroph cell at high magnification (40,0006; scale bar=0.1 micron) is shown in (C). An irregular organelle with normal
membrane thickness from a typical untreated arf1D cell at 8,0006(scale bar=0.5 micron) is shown in (D). A comparable structure exhibiting localized
membrane expansion in a 60 mM sertraline-treated arf1D cell at 8,0006(scale bar=0.5 micron) is shown in (E).
doi:10.1371/journal.pone.0034024.g007
Antidepressant Accumulation in Cellular Membranes
PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e34024mechanism would be expected to unfold over long time scales
given the vigilance of those buffering systems, and the large
effective volume of cellular membranes of the mammalian brain.
Materials and Methods
Yeast strains and culture conditions
Standard growth conditions were YPD media (1% yeast extract,
2% peptone and 2% dextrose) buffered with 10 mM HEPES to
the desired pH. Some experiments with prototrophic strains were
carried out in HEPES-buffered minimal media (yeast nitrogen
base containing ammonium sulfate, 2% dextrose). BY4716,
BY4742 or ACY769 were employed as wildtype reference strains
as appropriate, and are all derived from S288c. sert
R mutant
strains were previously described [12]. sert
HS deletion strains were
derived from ACY769 and belong to a prototrophic homozygous
deletion collection generated by D. Hess (Santa Clara University)
and A. Caudy (University of Toronto). The dnf1D dnf2D dnf3D
mutant was kindly provided by T. Graham (Vanderbilt). The
sec18
ts mutant was kindly provided by W. Prinz (NIH).
Chemical compounds
Sertraline hydrochloride (Sigma-Aldrich) was resuspended in
dimethyl sulfoxide (DMSO) to a final concentration of 25 mg/mL
(,73 mM), and 100 mL aliquots were stored in glass vials at
220uC until use and subjected to a maximum of one freeze/thaw
cycle. Sertraline [N-methyl-
3H] hydrochloride (American Radiol-
abled Chemicals, Inc.) is 99% pure by HPLC, has a specific
activity of 80 Ci/mmol, and was kept at a stock concentration of
1 mCi/mL in ethanol.
Pharmacological/biochemical assays and analysis
Overnight cultures were diluted in fresh pH-buffered YPD
medium and incubated at 30uC till log phase. Cell number and
cell size were determined by the Coulter counter method. For
uptake and accumulation experiments, 0.25 mCi
3H-sertraline
(American Radiolabeled Chemicals) was added to 2 mL yeast
culture aliquot (all 0-minute time point aliquots contained 1 mM
sodium azide and sodium fluoride). Cells were collected on
Durapore* PVDF filters (Millipore) by passing through a filter
unit, and washed with 18 ml ice cold pH-buffered YPD. Filters
were incubated with 300 mL cold lysis buffer (acetonitrile:metha-
nol:water, 40:40:20) at 220uC for 10 minutes. Cell pellets were
collected by pipetting and transferred to scintillation vials
containing 4 mL Cytoscint fluid (Fisher Scientific, Inc.). Counts
were obtained using a Perkin Elmer Tri-Carb 2800TR liquid
scintillation analyzer. For kinetic experiments, cells were incubated
with specified concentrations of [
3H]sertraline for 2 minutes, then
collected on filters and washed with ice cold YPD containing
10 mM unlabeled sertraline [39]. Subcellular fractionation was
carried out as follows. Cells were sphereplasted following
Zymolyase (Zymo Research) digestion at 30uC for 1 hour
according to manufacturers protocol. Spheroplasts were osmoti-
cally lysed in lysis buffer (50 mM Tris-HCl, 0.8 M sorbitol). The
resulting lysate was centrifuged at 400 rcf for 10 minutes, yielding
a post-nuclear lysate. An initial spin at 10,000 rcf for 10 minutes
yielded P10,000 (enriched in large organellar membranes) and
S10,000 fractions; S10,000 was spun at 100,000 rcf for 50 minutes,
yielding a microsomal (P100,000) and a true soluble fraction
(S100,000). All pellets were resuspended in equal volumes of the
same buffer as the corresponding supernatant fractions. For
experiments involving density-gradient centrifugation, the
10,000 rcf pellet obtained during fractionation was resuspended
in 1 mL 35% Optiprep solution (Sigma Aldrich), on top of which
Figure 8. The chc1 mutant exhibits unique adaptation to
chronic sertraline exposure. (A) A representative untreated chc1 cell
contains five electron-dense vacuoles (10,0006; scale bar=0.5 micron).
(B) A representative sertraline-treated chc1 cell contains a single
vacuole and four lipid droplets marked by red asterisks (10,0006; scale
bar=0.5 micron). (C) Quantification of lipid droplet formation in
untreated and sertraline-treated cells. The ‘‘-‘‘ column correspond to
lipid droplet counts performed on untreated cells. The ‘‘+’’ column
correspond to lipid droplet counts performed on cells treated with
60 mM sertraline for 45 minutes. The strain identities are: BY4716
(black); chc1 (red); swa2 (green); vma9 (magenta); arf1D (orange); drs2D
(yellow); sac1D (blue).
doi:10.1371/journal.pone.0034024.g008
Antidepressant Accumulation in Cellular Membranes
PLoS ONE | www.plosone.org 11 April 2012 | Volume 7 | Issue 4 | e340241 mL 30% Optiprep solution and 1 mL base solution (10 mM
Tris-HCl pH 7.4, 150 mM NaCl, 8% sucrose) were layered
consecutively. The gradient was centrifuged at 61,000 rpm for
17 hours and 45 minutes using a TLA100.3 rotor (Beckman). Ten
equal fractions were collected from each gradient. Optiprep
gradient fractions were pelleted with TCA, washed twice with ice-
cold acetone, and resuspended in 30 mL Nu-PAGE SDS sample
buffer (Invitrogen). Primary antibodies were used at the following
dilutions: the late-Golgi marker Vsp10p 1:250 (A-21274, Invitro-
gen); the vacuolar membrane marker ALP 1:500 (A-6458,
Invitrogen); the endoplasmic reticulum marker Dpm1p 1:2000
(A-6429, Invitrogen); the endosomal marker Pep12p 1:2000 (A-
21273, Invitrogen); the mitochondrial marker Porin 1:2000 (A-
6449, Invitrogen); carboxypeptidase Y (ab113685, Abcam); and
the plasma membrane marker Pma1p 1:10,000 (ab4645, Abcam).
For immunoblotting, total protein was transferred to PVDF
membrane after electrophoresis using the iBlot system (Invitrogen).
PVDF membranes were washed with SNAP I.D. Protein
Detection System (Millipore), and chemiluminescence was detect-
ed using ECL plus Western Blotting Substrate (Pierce). Analysis of
pharmacological data and figure generation were performed using
Prism 5 (GraphPad Software, Inc).
Transmission electron microscopy and analysis
We based our protocol on a membrane-preserving procedure
previously described [40]. Our step-by-step protocol is available as
Methods S1. 10 mL of fresh YPD media were inoculated with
cells from an overnight culture and allowed to double several times
to a maximum OD600 of ,0.5. For drug treatments, cells were
treated with 60 mM sertraline for 5, 10, 20 and 45 minutes. Multi-
cell and single-cell fields were collected. Quantification of
ultrastructural phenotypes was performed on a dataset compiled
from wide fields as previously described [12]. Wide-field cell
counts for the 45-minute dataset were as follows: BY4716
(untreated n=216, sertraline-treated n=193); prototroph (un-
treated n=247, sertraline-treated n=184); chc1 (untreated
n=234, sertraline-treated n=202); swa2 (untreated n=165,
sertraline-treated n=168); vma9 (untreated n=212, sertraline-
treated n=166); sac1D (untreated n=219, sertraline-treated
n=151); drs2D (untreated n=220, sertraline-treated n=158);
arf1D (untreated n=194, sertraline-treated n=133).
Supporting Information
Figure S1 Growth rate of BY4716 cells as a function of
sertraline concentration. Cells at optical density (OD600)
equal to 1.0 were used as the initial inoculum.
(TIFF)
Methods S1 Detailed protocol describing ‘‘ROTO’’
(Reduced Osmium tetroxide Thiocarbohydrazide - re-
duced Osmium) transmission electron microscopy.
(DOCX)
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